Business
Award of Innovative Medicines Initiative grant
Award of Innovative Medicines Initiative grant.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 7050G\n Cambridge Cognition Holdings PLC\n 19 March 2020\n \n \n \n \n 19 March 2020\n \n \n Cambridge Cognition Holdings Plc\n \n \n \n (\"\n \n \n Cambridge Cognition\"\n \n \n \n or the \"Company\")\n \n \n \n \n \n \n Cambridge Cognition awarded Innovative Medicines Initiative grant \n \n \n with partners from industry and academia \n \n \n \n \n \n Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess all aspects of cognition, is pleased to announce it is part of a successful consortium of 46 industry and academic partners who have collectively been awarded a prestigious Innovative Medicines Initiative (\"IMI\") grant. Led by the University of Newcastle, the consortium will work to identify digital endpoints for fatigue, sleep and activities of daily living in neurodegenerative disorders and immune-mediated inflammatory diseases. Cambridge Cognition will be the computerised cognitive assessment partner in the consortium and the proportion of the grant received by the Company is anticipated to be €150,000.\n \n \n The IMI grant will fund a new European research project to Identify Digital Endpoints to Assess FAtigue, Sleep and acTivities of daily living (acronym: \"IDEA-FAST\") in the following neurodegenerative disorders: Parkinson's disease and Huntington's disease, and in the following immune-mediated inflammatory diseases: rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's syndrome, and inflammatory bowel disease; has been launched. \n \n \n IDEA-FAST is a ground-breaking, €42 million digital health project co-funded by the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations) under the Innovative Medicines Initiative Joint Undertaking programme. It consists of 46 members from 14 different European countries, including Cambridge Cognition, pharmaceutical companies, academic and not-for-profit institutions, small- and medium-sized enterprises and patient organisations aiming to play complementary roles in achieving the agreed goals. \n \n \n Fatigue and sleep disturbances are common and disabling symptoms that affect patients with neurodegenerative disorders and immu...